首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1899964

治療性疫苗市場規模、佔有率和成長分析（按產品、技術和地區分類）－2026-2033年產業預測

Therapeutic Vaccines Market Size, Share, and Growth Analysis, By Products (Addiction Vaccines, Autoimmune Disease Vaccines), By Technology (Autologous vaccines, Allogeneic vaccines), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 215 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球治療性疫苗市場規模預計在 2024 年達到 593.5 億美元，從 2025 年的 655.8 億美元成長到 2033 年的 1,457.7 億美元，在預測期（2026-2033 年）內複合年成長率為 10.5%。

隨著疫苗被接種到接受慢性病治療的患者體內以增強其免疫反應並提高康復幾率，治療性疫苗市場正經歷顯著成長。慢性病盛行率的不斷上升，以及對創新疫苗研發投入的持續成長，預計將推動市場擴張。此外，全球範圍內預防保健意識的提高和對個人化醫療日益成長的需求，也進一步推動了對治療性疫苗的需求。然而，複雜的研發流程和有限的療效等挑戰可能會阻礙市場的長期發展。為了抓住新的機遇，治療性疫苗公司可以考慮在不斷變化的醫療保健環境中，將疫苗與各種免疫療法和精準醫療策略相結合。

全球治療性疫苗市場促進因素

全球感染疾病和慢性病盛行率的不斷上升，引發了公眾對醫療保健的日益關注，也激發了人們對治療性疫苗等創新解決方案的興趣。隨著個人和醫療系統尋求有效應對各種健康挑戰的途徑，人們對疾病預防重要性的認知不斷提高，預計將推動治療性疫苗的需求成長。隨著越來越多的人將接種疫苗作為積極主動的健康管理方式，治療性疫苗市場預計將迎來顯著成長。這反映了醫療保健優先事項的不斷變化以及為改善全球人民健康狀況所做的共同努力。

限制全球治療性疫苗市場的因素

全球治療性疫苗市場面臨許多限制因素，這些疫苗在最終惠及全球患者之前，必須經過嚴格的核准和測試流程。相關程序需要廣泛的評估，耗時且複雜，導致延誤，阻礙了新療法快速上市。漫長的核准週期最終限制了市場的成長潛力，因為緩慢的產品核可會扼殺創新，並限制有需要的患者獲得突破性治療方法的機會。

全球治療性疫苗市場趨勢

全球治療性疫苗市場正呈現出顯著的趨勢，即整合創新的免疫療法，尤其是在癌症治療領域。供應商正致力於開發針對特定腫瘤的特異性治療性疫苗，以調節其免疫反應。這項策略轉變旨在提高現有免疫療法的療效，並為患者提供更個人化和有效的治療方案。隨著我們對腫瘤免疫學的理解不斷加深，在對能夠更有效地利用人體免疫系統對抗癌症的標靶治療的需求驅動下，市場有望迎來成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

GlaxoSmithKline plc（GSK）（United Kingdom）
Sanofi SA（France）
Pfizer Inc.（United States）
Moderna, Inc.（United States）
BioNTech SE（Germany）
Bavarian Nordic A/S（Denmark）
Medigene AG（Germany）
Arbutus Biopharma Corporation（Canada）
Inovio Pharmaceuticals, Inc.（United States）
Dynavax Technologies Corporation（United States）
Agenus Inc.（United States）
Heat Biologics, Inc.（United States）
Northwest Biotherapeutics, Inc.（United States）
ImmunoCellular Therapeutics, Ltd.（United States）
Advaxis, Inc.（United States）
OncoSec Medical Incorporated（United States）
Vical Incorporated（United States）
Celldex Therapeutics, Inc.（United States）
Altimmune, Inc.（United States）

結論與建議

簡介目錄

Product Code: SQMIG35J2111

Global Therapeutic Vaccines Market size was valued at USD 59.35 Billion in 2024 and is poised to grow from USD 65.58 Billion in 2025 to USD 145.77 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026-2033).

The therapeutic vaccines market is experiencing significant growth as these vaccines are administered to enhance immune responses in patients undergoing treatment for chronic diseases, thereby improving recovery prospects. The increasing prevalence of chronic illnesses, coupled with heightened investments in research and development of innovative vaccines, is expected to drive market expansion. Additionally, there is a rising awareness of preventive healthcare and a growing preference for personalized medicine on a global scale, which further fuels demand for therapeutic vaccines. However, challenges such as the complex R&D processes and limited efficacy may hinder long-term market development. To create new opportunities, therapeutic vaccine companies can explore integration with various immunotherapies and precision medicine strategies in the evolving healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Vaccines Market Segments Analysis

Global Therapeutic Vaccines Market is segmented by Products, Technology and region. Based on Products, the market is segmented into Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines and Neurological Disease Vaccines. Based on Technology, the market is segmented into Autologous vaccines and Allogeneic vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Therapeutic Vaccines Market

The rising prevalence of infectious and chronic diseases globally has heightened public awareness of preventive healthcare, leading to an increased focus on innovative solutions such as therapeutic vaccines. This growing recognition of the importance of disease prevention is expected to drive demand for therapeutic vaccines, as individuals and healthcare systems alike seek effective measures to combat various health challenges. As more people prioritize vaccination as a proactive approach to health management, the therapeutic vaccines market stands poised for substantial growth, reflecting the evolving landscape of healthcare priorities and the collective push towards improved health outcomes for populations worldwide.

Restraints in the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market faces significant constraints due to the stringent approval and testing processes these vaccines must navigate prior to being available for patient use globally. The involved procedures require extensive evaluation and can be both lengthy and intricate, resulting in delays that hinder the prompt introduction of new therapies to the market. This protracted timeline ultimately restricts the growth potential of the market, as the slow pace of product approval can stall innovation and limit the availability of potentially groundbreaking treatments for patients in need.

Market Trends of the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market is experiencing a notable trend towards the integration of innovative immunotherapy approaches, particularly for cancer treatment. Vendors are increasingly focusing on the development of specialized therapeutic vaccines tailored to modulate immune responses specific to various tumors. This strategic pivot aims to enhance the efficacy rates of existing immunotherapies, providing more personalized and effective treatment options for patients. As understanding of tumor immunology advances, the market is poised for growth, driven by the need for improved targeted therapies that leverage the body's immune system to combat cancer more effectively.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Therapeutic Vaccines Market Size by Products & CAGR (2026-2033)

Market Overview
Addiction Vaccines
Autoimmune Disease Vaccines
Infectious Disease Vaccines
Neurological Disease Vaccines

Global Therapeutic Vaccines Market Size by Technology & CAGR (2026-2033)

Market Overview
Autologous vaccines
Allogeneic vaccines

Global Therapeutic Vaccines Market Size & CAGR (2026-2033)

North America (Products, Technology)
- US
- Canada
Europe (Products, Technology)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Products, Technology)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Products, Technology)
- Brazil
- Rest of Latin America
Middle East & Africa (Products, Technology)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bavarian Nordic A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigene AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arbutus Biopharma Corporation (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heat Biologics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Northwest Biotherapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmunoCellular Therapeutics, Ltd. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advaxis, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoSec Medical Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vical Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celldex Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altimmune, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments